Screening for Substance Use Disorders/Opioid Use Disorder

This revised version of the CRAFFT screening tool incorporates changes that enhance the sensitivity of this well-validated and widely-utilized adolescent substance use screening tool to accurately identify adolescents at risk for a substance use disorder. It also presents new recommended clinician talking points, informed by the latest science and clinician feedback.

The Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS) Tool consists of a combined screening component (TAPS-1) followed by a brief assessment (TAPS-2) for those who screen positive.

This guide will explans how to choose a screening tool for Perinatal Mood and Anxiety Disorders (PMADs), provides recommendations and resources on how to administer the tools, recommends additional screening tools, presents an algorithm and response protocol, and briefly touches on establishing outside resources and referrals.

This toolkit provides tools to both providers and patients for the assessment and management of perinatal mood and anxiety disorders, as well as substance use disorders (SUD).

This guidance provides recommendations for screening pregnant patients for substance use disorder (SUD) to enhance the well-being of the maternalfetal dyad.

MCPAP for Moms provides obstetricians, midwives, and PCPs with psychiatric consultation for behavioral health concerns and questions around medications when pregnant or breastfeeding. MCPAP for Moms also supports connections with community-based services and support groups.

This implementation guide serves to provide other medical clinics seeking to integrate maternal mental health care into obstetric and/or pediatric settings with best practices for doing so.

This report describes changes in drug overdose death rates from 2019 to 2020, stratified by sex, age group, and race and ethnicity. In addition, it examines differences in circumstances surrounding drug overdose, and assesses differences in overdose death rates by county-level income inequality and availability of mental health treatment providers and providers of medications for opioid use disorder.

Based on 2020 and earlier NSDUH data, this report contains findings on a wide variety of key substance use and mental health indicators in the United States.

This data visualization presents provisional counts for drug overdose deaths based on a current flow of mortality data in the National Vital Statistics System.